WP Advisors LLC Invests $211,000 in Novo Nordisk A/S (NYSE:NVO)

WP Advisors LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 1,480 shares of the company’s stock, valued at approximately $211,000.

Other large investors also recently modified their holdings of the company. First PREMIER Bank acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter worth $25,000. 1620 Investment Advisors Inc. acquired a new stake in Novo Nordisk A/S in the second quarter valued at about $25,000. Dixon Mitchell Investment Counsel Inc. acquired a new stake in Novo Nordisk A/S in the first quarter valued at about $26,000. Orion Capital Management LLC acquired a new stake in Novo Nordisk A/S in the first quarter valued at about $26,000. Finally, Gilliland Jeter Wealth Management LLC boosted its stake in Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after buying an additional 120 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 1.2 %

Novo Nordisk A/S stock traded up $1.64 during mid-day trading on Friday, reaching $139.16. The stock had a trading volume of 2,718,338 shares, compared to its average volume of 4,368,564. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. Novo Nordisk A/S has a fifty-two week low of $86.96 and a fifty-two week high of $148.15. The stock’s 50-day simple moving average is $135.76 and its 200-day simple moving average is $132.06. The firm has a market capitalization of $624.48 billion, a PE ratio of 47.99, a price-to-earnings-growth ratio of 1.33 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). The company had revenue of $9.82 billion for the quarter, compared to analysts’ expectations of $9.91 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.38 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were given a $0.5126 dividend. The ex-dividend date was Friday, August 16th. This represents a yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio is currently 24.83%.

Analysts Set New Price Targets

NVO has been the subject of several research reports. The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a research report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price for the company. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 19th. BMO Capital Markets dropped their target price on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Monday, August 19th. Finally, Argus increased their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average price target of $145.17.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.